RCM
BDTX icon

RB Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

RB Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$185K Buy
100,000
+65,000
+186% +$159K 0.04% 197
2026
Q1 		$74.5K Hold
35,000
– – 0.02% 184
2025
Q4 		$85K Buy
+35,000
New +$124K 0.02% 194

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

RB Capital Management's BDTX Position: Q2 2026 in Review

RB Capital Management increased its Black Diamond Therapeutics (BDTX) stake by 186% in Q2 2026, buying an estimated $159K and bringing the position to 100,000 shares worth $185K. The position accounts for 0.04% of the portfolio, ranked #197.

RB Capital Management first reported a position in BDTX in Q4 2025 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • RB Capital Management held 100,000 shares of Black Diamond Therapeutics worth $185K as of Q2 2026.
  • RB Capital Management bought 65,000 Black Diamond Therapeutics shares in Q2 2026, an estimated $159K.
  • Black Diamond Therapeutics made up 0.04% of RB Capital Management's portfolio in Q2 2026, its #197 holding.
  • RB Capital Management first reported a position in Black Diamond Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on RB Capital Management's 13F filing for Q2 2026, filed 18 Aug 2026.